A hospital anesthetic repackaged as fruit-flavored vape oil has fueled a 900-fold surge in drug detections, deadly crashes, and Taiwan's toughest narcotics upgrade in years — and experts warn the crisis is regional, not local.
In the first three months of 2026 alone, Taiwan recorded 113 traffic crashes involving drivers under the influence of drugs, leaving at least six people dead and 105 injured. Behind many of these cases is a substance most Taiwanese had never heard of three years ago: etomidate, a fast-acting hospital anesthetic now being dissolved into e-cigarette oil and sold on the street as the so-called "zombie vape pod" (喪屍煙彈) or "K-pods".
The nickname is grimly literal. Videos circulating on Threads and other platforms show young people on Taiwan's streets swaying, trembling, and folding at the waist, unable to control their limbs — scenes that echo the fentanyl-ravaged sidewalks of San Francisco, though the drug and the chemistry are entirely different.
Two recent cases crystallized public alarm. In New Taipei, a driver who had inhaled an etomidate-laced pod plowed into a motorcyclist at high speed, killing one person and severely injuring another. In Changhua, a drugged driver racing across an overpass struck a motorcyclist and then a passenger car, leaving two people dead.
On June 27, Taiwan's government responded by elevating etomidate to a Category 1 narcotic — the same legal tier as heroin — making its manufacture, transport, or sale punishable by death or life imprisonment.
From 22 Detections to 20,727: How Fast the Drug Took Hold
Official data traces an almost vertical trajectory. According to Taiwan's Food and Drug Administration, etomidate was first detected in the illicit drug supply in November 2023, with just 22 cases recorded in that initial period. By 2025, detections had exploded to 20,727 — an increase of more than 900-fold in roughly two years.
The regulatory ladder climbed almost as quickly. Etomidate was listed as a Category 4 controlled substance in August 2024, reclassified as a Category 2 narcotic that November, and finally upgraded to Category 1 in June 2026.
Drugged-driving enforcement figures tell the same story. Interior Ministry data show police recorded 2,619 drugged-driving cases in all of 2024. In 2025, that number more than tripled to 8,659. In just the first four months of 2026, it had already reached 4,725.
Seizure statistics released by the National Police Agency in December 2025 show that among Category 2 narcotics confiscated between January and May of that year, etomidate ranked second by weight at 548.7 kilograms (33.4%) — behind cannabis at 689.4 kilograms but ahead of methamphetamine at 301.9 kilograms.
Young Users Dominate the Numbers
The demographic profile of the crisis is unmistakably young. Of 8,392 etomidate-related criminal suspects, the 18-to-23 age bracket showed the highest per-capita offense rate at 126.75 per 100,000, followed by the 24-to-29 group at 80.92.
Part of the drug's appeal was manufactured before it was even illegal. In 2024, prior to etomidate's scheduling, sellers marketed it under brand names promising a "cannabis substitute" for relaxation and a "space flight" high — a framing that seeded a dangerous myth of harmlessness.
Dr. Lee Chun-hung (李俊宏), a board director of the Taiwanese Society of Addiction Science and deputy superintendent of Taoyuan Psychiatric Center, told Storm Media in an interview that the drug's pharmacology is precisely what makes it marketable. Etomidate reaches the body within roughly 8 to 10 seconds of inhalation, takes effect within minutes, and is metabolized within hours — far shorter than heroin's four-to-six-hour window or methamphetamine's 10 to 20 hours.
"That means users can vape after class or before work and appear normal a short time later," Lee explained. The drug's brief footprint makes habitual use easy to conceal from family, teachers, and employers.
A Doctor's Warning: 'This Pod Is Not the Next Pod'
Lee is emphatic that short-acting does not mean safe. The core danger, he said, is that no two pods are alike.
"I've had patients tell me they felt nothing — no weakness, no tremors — so they assumed it was no big deal," Lee recounted. "I tell them: the pod you used this time and the pod you use next time may come from different dealers, with different formulas and different concentrations. Being fine this time doesn't mean the next puff will be."
Because etomidate is an anesthetic, users lose fine motor control after inhaling. For anyone with underlying neurological or cardiovascular conditions, Lee warned, the drug carries a real risk of sudden death. And unlike in an operating room, where trained clinicians control every milligram, street pods are dosed by no one.
Worse, they rarely contain etomidate alone. "Whether to evade detection, cut costs, or as byproducts of sloppy synthesis, we've seen substances like metomidate mixed in clinically — even veterinary anesthetics," Lee said.
Long-term consequences are only now surfacing. Lee's clinic is beginning to see withdrawal cases presenting with anxiety, insomnia, irritability, and depression; hyperpigmentation and cardiac arrhythmia have also been observed, the latter potentially fatal. Because the drug's recreational history spans barely three years, he stressed, Taiwan urgently needs its own domestic research to understand the full damage profile.
A Regional Epidemic That Started in China
Taiwan's outbreak is one front in a wider Asian crisis. Etomidate-laced vapes were first identified in China in 2021, and the trade has since spread across East and Southeast Asia. According to a September 2025 report by The Diplomat, the drug has been detected from Singapore and Thailand to Cambodia, Indonesia, and Malaysia — sold openly on platforms including Lazada, TikTok, and Telegram to buyers as young as 13, with no age verification, candy-colored packaging, influencer endorsements, and false claims that the drug evades urine testing.
The user base skews young everywhere. The Diplomat's reporting cited figures showing 82% of Cambodia's vape users are aged 15 to 35, while more than half of those caught vaping in Singapore are under 30. A local expert quoted in the report observed that most young users have no idea what they are inhaling, treating drug-laced pods as just another vape variant.
Japan has not been spared. The South China Morning Post reported in late 2025 on the drug's growing grip on youth in southern Japan, with 10 people arrested in Okinawa for etomidate possession by the end of September — most in their teens and twenties.
Even Singapore, one of the world's first countries to ban e-cigarettes outright, has struggled. The BBC has documented the city-state's escalating crackdown — heavier fines, longer sentences, even caning — after videos of "zombified" young users flooded social media. Yet as The Straits Times reported in May 2026, a single enforcement operation in late April caught three people vaping — the youngest just 11 years old — and arrested a 17-year-old for repeat etomidate use. Harsh penalties alone, the episode suggests, cannot root the drug out.
Lee sees a clear transmission pattern. Roughly 700 to 800 new psychoactive substances are synthesized globally each year, he noted, and etomidate followed a path from China outward. "From around late 2023, when China placed it under narcotics control, we very quickly saw it move from China's southeastern coast into East Asia — Taiwan, Hong Kong, Macau, then more recently Japan and Korea," he said. "The two sides of the strait are simply too close. We cannot afford to be complacent about drug-use patterns emerging in China."
Why It Spread So Fast: Three Structural Drivers
Lee identifies three forces behind the drug's velocity.
First, the delivery device is camouflage. Flavored e-cigarette pods smell like fruit, making a drugged pod indistinguishable from an ordinary one — and in jurisdictions where vaping is legal (it is banned in Taiwan), police have little basis to stop and check. Vaping itself has become normalized among Taiwanese youth: national health surveys show that while conventional smoking among middle and high school students has declined year over year, e-cigarette use surged, and even after a recent dip, roughly 5.1% — more than 20,000 high schoolers — have used or currently use vapes. For them, Lee said, trying the drug "is just a matter of swapping the pod."
Second, online sales channels offer anonymity and reach that street dealing never could, making the trade hard to trace and easy to spread through youth networks — the same dynamic The Diplomat documented across Southeast Asia.
Third, the drug's rapid onset and rapid exit make use nearly invisible. A Singaporean psychiatrist quoted by The Diplomat noted that the faster a drug delivers its high and the fewer its immediate after-effects, the more addictive it tends to be — a description etomidate fits precisely. Peer culture accelerates everything: an invitation to "try a new flavor" that "relieves stress" and "did nothing bad to me" is often all it takes. And because etomidate is cheaply synthesized — no poppy fields required — it sits within a teenager's budget.
Drugged Driving Is Not Addiction — And Taiwan Is Treating Them Differently
As death tolls mounted, so did public demands for harsher punishment. Lee argues the two problems must be separated. Not every user is addicted, he said, and those who are need medical treatment — harm reduction along a gradual path toward full abstinence.
Drugged driving is another matter entirely. "That is a public safety issue — zero tolerance," Lee said, regardless of whether the driver has a dependency. He supports Taiwan's tough new penalties and advocates higher police visibility and more checkpoints along major corridors and known hot zones.
Taiwan's 2026 legal overhaul reflects that hard line. Refusing a roadside drug test now draws a NT$270,000 fine for a first offense, with NT$180,000 added for each repeat, uncapped. Any vehicle used in drugged driving is confiscated regardless of who owns it, and the driver's license is revoked. First-time drugged drivers face fines of NT$120,000 (cars) or NT$90,000 (motorcycles), rising NT$90,000 per repeat offense without limit; a second offense triggers a lifetime ban on obtaining a license. Repeat drug- or drunk-driving offenders within five years are ineligible for parole. Users of Category 1 narcotics face six months to five years in prison.
Enforcement Alone Won't End It, Expert Says
Can severe punishment eradicate the drug? Lee is skeptical, pointing to basic market dynamics: crackdowns raise prices, and priced-out users simply migrate to cheaper alternatives — of which the global drug trade produces new ones almost weekly.
He offers a cautionary precedent. In 2008, a 50-ton seizure of MDMA precursors in Thailand and neighboring countries broke the ecstasy supply chain across Asia and into Europe. Dealers responded with a reformulated, far deadlier variant — one that killed roughly 200 people in Taiwan.
"The demand for drugs was always there," Lee said. "These young people didn't start using because etomidate appeared. They were already a population inclined toward addictive substances — and whenever something more convenient comes along, they will use it."
The durable answers, he argues, lie at both ends of the supply chain. On supply, Lee wants uniform, severe penalties for large-scale manufacturing, transport, and importation regardless of a drug's category tier: "Bringing tons of any narcotic into Taiwan is a malicious crime against the physical and mental health of Taiwanese people. It shouldn't be graded — it should all be punished heavily."
On demand, the answer is harder and slower. Youth suicide rates are climbing across China, Taiwan, Japan, and Korea alike, he noted — a red light flashing over adolescent mental health worldwide. "Without a comprehensive approach to young people's mental health — from the individual to the family to the community — this empty generation will keep reaching for drugs," Lee said. Improving public understanding of mental illness and addiction, he added, is the surest way to shrink the market that no crackdown can close.
You Can't Miss More In-depth Stories :
